X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (192) 192
oncology (129) 129
index medicus (118) 118
female (111) 111
male (110) 110
in situ hybridization, fluorescence (81) 81
lung neoplasms - genetics (77) 77
article (75) 75
middle aged (71) 71
aged (58) 58
carcinoma, non-small-cell lung - genetics (53) 53
adult (51) 51
lung neoplasms - drug therapy (51) 51
cancer (47) 47
carcinoma, non-small-cell lung - drug therapy (47) 47
biochemistry (43) 43
chemistry (42) 42
beer (41) 41
compositions or test papers therefor (41) 41
condition-responsive control in microbiological orenzymological processes (41) 41
enzymology (41) 41
lung neoplasms - pathology (41) 41
measuring or testing processes involving enzymes, nucleicacids or microorganisms (41) 41
metallurgy (41) 41
microbiology (41) 41
mutation or genetic engineering (41) 41
processes of preparing such compositions (41) 41
spirits (41) 41
vinegar (41) 41
wine (41) 41
expression (37) 37
mutation (36) 36
lung cancer (34) 34
receptor, epidermal growth factor - genetics (33) 33
gefitinib (31) 31
gene amplification (31) 31
mutations (31) 31
respiratory system (31) 31
cell line, tumor (29) 29
genetics & heredity (27) 27
prognosis (27) 27
tumors (26) 26
aged, 80 and over (25) 25
animals (25) 25
fish (25) 25
carcinoma, non-small-cell lung - pathology (24) 24
mice (24) 24
antineoplastic agents - therapeutic use (23) 23
chemotherapy (22) 22
chromosome aberrations (22) 22
gene dosage (21) 21
immunohistochemistry (21) 21
amplification (20) 20
egfr (20) 20
gene rearrangement (20) 20
survival (20) 20
therapy (20) 20
adenocarcinoma - genetics (19) 19
cell biology (19) 19
copy number (18) 18
derivatives thereof (18) 18
gene copy number (18) 18
gene expression regulation, neoplastic (18) 18
nucleic acids (18) 18
nucleosides (18) 18
nucleotides (18) 18
organic chemistry (18) 18
protein kinase inhibitors - therapeutic use (18) 18
proto-oncogene proteins - genetics (18) 18
quinazolines - therapeutic use (18) 18
sugars (18) 18
adenocarcinoma (17) 17
crizotinib (17) 17
treatment outcome (17) 17
biochemistry & molecular biology (16) 16
breast-cancer (16) 16
erlotinib (16) 16
fluorescence in situ hybridization (16) 16
gene (16) 16
investigating or analysing materials by determining theirchemical or physical properties (16) 16
karyotyping (16) 16
lung neoplasms - mortality (16) 16
measuring (16) 16
physics (16) 16
research (16) 16
testing (16) 16
carcinoma (15) 15
carcinoma, non-small-cell lung - mortality (15) 15
carcinoma, squamous cell - genetics (15) 15
digeorge syndrome (15) 15
fluorescence (15) 15
receptor, epidermal growth factor - antagonists & inhibitors (15) 15
analysis (14) 14
antineoplastic agents - pharmacology (14) 14
cell lung-cancer (14) 14
identification (14) 14
in-situ hybridization (14) 14
lung neoplasms - enzymology (14) 14
lung neoplasms - metabolism (14) 14
receptor, epidermal growth factor - metabolism (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 10, pp. 1011 - 1019
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S181 - S182
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 11, pp. 1004 - 1012
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 21, pp. 1963 - 1971
Journal Article
JAMA, ISSN 0098-7484, 05/2014, Volume 311, Issue 19, pp. 1998 - 2006
Journal Article
Journal of Cancer, ISSN 1837-9664, 2016, Volume 7, Issue 6, pp. 633 - 649
The MET signaling pathway plays an important role in normal physiology and its deregulation has proved critical for development of numerous solid tumors.... 
FISH | Molecular testing | IHC | Targeted therapy | MET | HGF | targeted therapy | molecular testing | PAPILLARY RENAL-CARCINOMAS | HEPATOCYTE GROWTH-FACTOR | METASTATIC COLORECTAL-CANCER | NEGATIVE BREAST-CANCER | CELL LUNG-CANCER | ONCOLOGY | RANDOMIZED PHASE-II | C-MET | GENE COPY NUMBER | NF-KAPPA-B | RECEPTOR TYROSINE KINASE
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2010, Volume 363, Issue 18, pp. 1693 - 1703
A small group of patients with non–small-cell lung cancer have genetic lesions that activate anaplastic lymphoma kinase (ALK). Crizotinib, an orally... 
ALK | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | 2ND-LINE TREATMENT | PHASE-II | IDENTIFICATION | TUMORS | ACTIVATING MUTATIONS | EGFR | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Microtubule-Associated Proteins - genetics | Humans | Middle Aged | Receptors, Growth Factor - antagonists & inhibitors | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Pyridines - adverse effects | Serine Endopeptidases - genetics | Cell Cycle Proteins - genetics | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Pyridines - administration & dosage | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Receptor Protein-Tyrosine Kinases | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Lung cancer, Small cell | Genetic aspects | Diagnosis | Health aspects | Phosphotransferases | Lymphomas | Pharmaceutical industry | Lung cancer | Tumors
Journal Article
Nature Genetics, ISSN 1061-4036, 10/2012, Volume 44, Issue 10, pp. 1111 - 1116
Journal Article
Nature Medicine, ISSN 1078-8956, 11/2013, Volume 19, Issue 11, pp. 1469 - 1472
Journal Article